Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Meeting Abstract
| Authors: | Sangro, B.; Galle, P. R.; Kelley, R. K.; Charoentum, C.; De Toni, E. N.; Ostapenko, Y.; Heo, J.; Cheng, A. L.; Vogel, A.; Marcovitz, M.; Abraham, J.; Patel, N.; Negro, A.; Abou-Alfa, G. K. |
| Abstract Title: | Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301240 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.4074 |
| Notes: | Meeting Abstract: 4074 -- Meeting also held virtually -- Source: Wos |
